Cargando…
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Background Venous thromboembolism (VTE) is a common complication in cancer patients. Much of its morbidity stems from the development of fatal pulmonary embolisms (PE). Little is known about the factors involved in clot stability, with angiogenesis possibly being implicated. Methods The database i...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512585/ https://www.ncbi.nlm.nih.gov/pubmed/35381615 http://dx.doi.org/10.1055/a-1816-8347 |
_version_ | 1784797863080886272 |
---|---|
author | Carmona-Bayonas, Alberto Verso, Melina Sánchez Cánovas, Manuel Rubio Pérez, Jaime García de Herreros, Marta Martínez del Prado, Purificación Fernández Pérez, Isaura Quintanar Verduguez, Teresa Obispo Portero, Berta Pachón Olmos, Vanessa Gómez, David Ortega, Laura Serrano Moyano, Marta M. Brozos, Elena Biosca, Mercedes Antonio Rebollo, Maite Teijeira Sanchez, Lucía Hernández Pérez, Carolina David Cumplido Burón, José Martínez Lago, Nieves García Pérez, Estefanía Muñoz Langa, Jose Pérez Segura, Pedro Martínez de Castro, Eva Jimenez-Fonseca, Paula Agnelli, Giancarlo Muñoz, Andrés |
author_facet | Carmona-Bayonas, Alberto Verso, Melina Sánchez Cánovas, Manuel Rubio Pérez, Jaime García de Herreros, Marta Martínez del Prado, Purificación Fernández Pérez, Isaura Quintanar Verduguez, Teresa Obispo Portero, Berta Pachón Olmos, Vanessa Gómez, David Ortega, Laura Serrano Moyano, Marta M. Brozos, Elena Biosca, Mercedes Antonio Rebollo, Maite Teijeira Sanchez, Lucía Hernández Pérez, Carolina David Cumplido Burón, José Martínez Lago, Nieves García Pérez, Estefanía Muñoz Langa, Jose Pérez Segura, Pedro Martínez de Castro, Eva Jimenez-Fonseca, Paula Agnelli, Giancarlo Muñoz, Andrés |
author_sort | Carmona-Bayonas, Alberto |
collection | PubMed |
description | Background Venous thromboembolism (VTE) is a common complication in cancer patients. Much of its morbidity stems from the development of fatal pulmonary embolisms (PE). Little is known about the factors involved in clot stability, with angiogenesis possibly being implicated. Methods The database is from the TESEO prospective registry that recruits cancer patients with VTE from 41 Spanish hospitals. Independent validation was conducted in a cohort from the Caravaggio trial. The objective is to evaluate the association between exposure to antiangiogenic therapies and the PE/VTE proportion in oncological patients. Results In total, 1,536 subjects were evaluated; 58.4% ( n = 894) had a PE and 7% ( n = 108) received antiangiogenic therapy (bevacizumab in 75%). The PE/VTE proportion among antiangiogenic-treated individuals was 77/108 (71.3%) versus 817/1,428 (57.2%) among those receiving other alternative therapies ( p = 0.004). The effect of the antiangiogenics on the PE/VTE proportion held up across all subgroups except for active smokers or those with chronic obstructive pulmonary disease. Exposure to antiangiogenics was associated with increased PEs, odds ratio (OR) 2.27 (95% CI, 1.42–3.63). In the Caravaggio trial, PE was present in 67% of the individuals treated with antiangiogenics, 50% of those who received chemotherapy without antiangiogenic treatment, and 60% without active therapy ( p = 0.0016). Conclusion Antiangiogenics are associated with increased proportion of PE in oncological patients with VTE. If an effect on clot stability is confirmed, the concept of thrombotic risk in cancer patients should be reconsidered in qualitative terms. |
format | Online Article Text |
id | pubmed-9512585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-95125852022-09-27 Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial Carmona-Bayonas, Alberto Verso, Melina Sánchez Cánovas, Manuel Rubio Pérez, Jaime García de Herreros, Marta Martínez del Prado, Purificación Fernández Pérez, Isaura Quintanar Verduguez, Teresa Obispo Portero, Berta Pachón Olmos, Vanessa Gómez, David Ortega, Laura Serrano Moyano, Marta M. Brozos, Elena Biosca, Mercedes Antonio Rebollo, Maite Teijeira Sanchez, Lucía Hernández Pérez, Carolina David Cumplido Burón, José Martínez Lago, Nieves García Pérez, Estefanía Muñoz Langa, Jose Pérez Segura, Pedro Martínez de Castro, Eva Jimenez-Fonseca, Paula Agnelli, Giancarlo Muñoz, Andrés Thromb Haemost Background Venous thromboembolism (VTE) is a common complication in cancer patients. Much of its morbidity stems from the development of fatal pulmonary embolisms (PE). Little is known about the factors involved in clot stability, with angiogenesis possibly being implicated. Methods The database is from the TESEO prospective registry that recruits cancer patients with VTE from 41 Spanish hospitals. Independent validation was conducted in a cohort from the Caravaggio trial. The objective is to evaluate the association between exposure to antiangiogenic therapies and the PE/VTE proportion in oncological patients. Results In total, 1,536 subjects were evaluated; 58.4% ( n = 894) had a PE and 7% ( n = 108) received antiangiogenic therapy (bevacizumab in 75%). The PE/VTE proportion among antiangiogenic-treated individuals was 77/108 (71.3%) versus 817/1,428 (57.2%) among those receiving other alternative therapies ( p = 0.004). The effect of the antiangiogenics on the PE/VTE proportion held up across all subgroups except for active smokers or those with chronic obstructive pulmonary disease. Exposure to antiangiogenics was associated with increased PEs, odds ratio (OR) 2.27 (95% CI, 1.42–3.63). In the Caravaggio trial, PE was present in 67% of the individuals treated with antiangiogenics, 50% of those who received chemotherapy without antiangiogenic treatment, and 60% without active therapy ( p = 0.0016). Conclusion Antiangiogenics are associated with increased proportion of PE in oncological patients with VTE. If an effect on clot stability is confirmed, the concept of thrombotic risk in cancer patients should be reconsidered in qualitative terms. Georg Thieme Verlag KG 2022-06-18 /pmc/articles/PMC9512585/ /pubmed/35381615 http://dx.doi.org/10.1055/a-1816-8347 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited. |
spellingShingle | Carmona-Bayonas, Alberto Verso, Melina Sánchez Cánovas, Manuel Rubio Pérez, Jaime García de Herreros, Marta Martínez del Prado, Purificación Fernández Pérez, Isaura Quintanar Verduguez, Teresa Obispo Portero, Berta Pachón Olmos, Vanessa Gómez, David Ortega, Laura Serrano Moyano, Marta M. Brozos, Elena Biosca, Mercedes Antonio Rebollo, Maite Teijeira Sanchez, Lucía Hernández Pérez, Carolina David Cumplido Burón, José Martínez Lago, Nieves García Pérez, Estefanía Muñoz Langa, Jose Pérez Segura, Pedro Martínez de Castro, Eva Jimenez-Fonseca, Paula Agnelli, Giancarlo Muñoz, Andrés Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial |
title | Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial |
title_full | Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial |
title_fullStr | Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial |
title_full_unstemmed | Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial |
title_short | Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial |
title_sort | do antiangiogenics promote clot instability? data from the teseo prospective registry and caravaggio clinical trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512585/ https://www.ncbi.nlm.nih.gov/pubmed/35381615 http://dx.doi.org/10.1055/a-1816-8347 |
work_keys_str_mv | AT carmonabayonasalberto doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT versomelina doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT sanchezcanovasmanuel doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT rubioperezjaime doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT garciadeherrerosmarta doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT martinezdelpradopurificacion doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT fernandezperezisaura doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT quintanarverduguezteresa doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT obispoporteroberta doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT pachonolmosvanessa doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT gomezdavid doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT ortegalaura doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT serranomoyanomarta doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT mbrozoselena doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT bioscamercedes doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT antoniorebollomaite doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT teijeirasanchezlucia doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT hernandezperezcarolina doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT davidcumplidoburonjose doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT martinezlagonieves doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT garciaperezestefania doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT munozlangajose doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT perezsegurapedro doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT martinezdecastroeva doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT jimenezfonsecapaula doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT agnelligiancarlo doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial AT munozandres doantiangiogenicspromoteclotinstabilitydatafromtheteseoprospectiveregistryandcaravaggioclinicaltrial |